1. Home
  2. SLS vs INVE Comparison

SLS vs INVE Comparison

Compare SLS & INVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLS
  • INVE
  • Stock Information
  • Founded
  • SLS 2012
  • INVE 1990
  • Country
  • SLS United States
  • INVE United States
  • Employees
  • SLS N/A
  • INVE N/A
  • Industry
  • SLS Biotechnology: Pharmaceutical Preparations
  • INVE Computer peripheral equipment
  • Sector
  • SLS Health Care
  • INVE Technology
  • Exchange
  • SLS Nasdaq
  • INVE Nasdaq
  • Market Cap
  • SLS 100.6M
  • INVE 82.2M
  • IPO Year
  • SLS N/A
  • INVE 1997
  • Fundamental
  • Price
  • SLS $1.27
  • INVE $3.44
  • Analyst Decision
  • SLS
  • INVE Strong Buy
  • Analyst Count
  • SLS 0
  • INVE 2
  • Target Price
  • SLS N/A
  • INVE $7.25
  • AVG Volume (30 Days)
  • SLS 4.1M
  • INVE 31.8K
  • Earning Date
  • SLS 03-27-2025
  • INVE 03-05-2025
  • Dividend Yield
  • SLS N/A
  • INVE N/A
  • EPS Growth
  • SLS N/A
  • INVE N/A
  • EPS
  • SLS N/A
  • INVE 3.10
  • Revenue
  • SLS N/A
  • INVE $104,217,000.00
  • Revenue This Year
  • SLS N/A
  • INVE N/A
  • Revenue Next Year
  • SLS N/A
  • INVE N/A
  • P/E Ratio
  • SLS N/A
  • INVE $1.13
  • Revenue Growth
  • SLS N/A
  • INVE 70.57
  • 52 Week Low
  • SLS $0.77
  • INVE $2.95
  • 52 Week High
  • SLS $1.84
  • INVE $9.24
  • Technical
  • Relative Strength Index (RSI)
  • SLS 50.97
  • INVE 40.36
  • Support Level
  • SLS $1.20
  • INVE $3.41
  • Resistance Level
  • SLS $1.37
  • INVE $3.67
  • Average True Range (ATR)
  • SLS 0.14
  • INVE 0.19
  • MACD
  • SLS -0.02
  • INVE 0.01
  • Stochastic Oscillator
  • SLS 10.94
  • INVE 12.20

About SLS SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

About INVE Identiv Inc.

Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.

Share on Social Networks: